Literature DB >> 31232238

Hotspot Mutations in DICER1 Causing GLOW Syndrome-Associated Macrocephaly via Modulation of Specific microRNA Populations Result in the Activation of PI3K/ATK/mTOR Signaling.

Steven D Klein1, Julian A Martinez-Agosto1,2.   

Abstract

BACKGROUND: We have previously described mosaic mutations in the RNase IIIb domain of DICER1that display global developmental delays, lung cysts, somatic overgrowth, macrocephaly and Wilms tumor. This constellation of phenotypes was classified as GLOW syndrome. Due to the phenotypic overlap between GLOW and syndromes caused by mutations in the PI3K/AKT/mTOR pathway, we hypothesized that alterations in miRNA regulation of this pathway cause its specific constellation of phenotypes.
OBJECTIVE: To test the hypothesis that DICER1 "hot spot" mutations associated with GLOW syndrome activate PI3K/AKT/mTOR signaling.
METHODS: We developed HEK293T cells with loss of exon 25 in DICER1, a genetic modification that is synonymous with the "hot spot" RNAseIIIb mutations that cause GLOW syndrome. We assayed the cells for activation of the PI3K/AKT/mTOR signaling pathway.
RESULTS: We observed activation of the PI3K/AKT/mTOR pathway as demonstrated by increased pS6Kinase, p4EBP1 and pTSC2 levels. Additionally, these cells demonstrate a striking cellular phenotype, with the ability to form spheres when the serum is removed from their growth medium. The cells in these spheres are Oct4 and Sox2 positive and exhibit the property of reversion with the addition of serum. We queried miRNA expression data and identified a population of miRNAs that increase due to these mutations and target negative regulators of the PI3K/AKT/mTOR pathway.
CONCLUSION: This work identifies the delicate and essential role for miRNA control of the PI3K/AKT/mTOR pathway. We conclude that the phenotypes observed in the GLOW syndrome are the result of PI3K/AKT/mTOR activation. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Cancer; DICER1; PI3K/AKT/mTOR; hot spot ; micoRNA; overgrowth.

Mesh:

Substances:

Year:  2020        PMID: 31232238      PMCID: PMC8405056          DOI: 10.2174/2211536608666190624114424

Source DB:  PubMed          Journal:  Microrna


  21 in total

Review 1.  miRNA Nomenclature: A View Incorporating Genetic Origins, Biosynthetic Pathways, and Sequence Variants.

Authors:  T Desvignes; P Batzel; E Berezikov; K Eilbeck; J T Eppig; M S McAndrews; A Singer; J H Postlethwait
Journal:  Trends Genet       Date:  2015-10-08       Impact factor: 11.639

2.  Lethal genes surviving by mosaicism: a possible explanation for sporadic birth defects involving the skin.

Authors:  R Happle
Journal:  J Am Acad Dermatol       Date:  1987-04       Impact factor: 11.527

Review 3.  Gynecologic Manifestations of the DICER1 Syndrome.

Authors:  Colin J R Stewart; Adrian Charles; William D Foulkes
Journal:  Surg Pathol Clin       Date:  2016-04-09

4.  Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis.

Authors:  Andreas Rohner; Ulrich Langenkamp; Uwe Siegler; Christian P Kalberer; Aleksandra Wodnar-Filipowicz
Journal:  Leuk Res       Date:  2007-03-27       Impact factor: 3.156

Review 5.  Type I pleuropulmonary blastoma: pathology and biology study of 51 cases from the international pleuropulmonary blastoma registry.

Authors:  Dana Ashley Hill; Jason A Jarzembowski; John R Priest; Gretchen Williams; Peter Schoettler; Louis P Dehner
Journal:  Am J Surg Pathol       Date:  2008-02       Impact factor: 6.394

Review 6.  DICER1 pleuropulmonary blastoma familial tumour predisposition syndrome: What the paediatric urologist needs to know.

Authors:  Alice Faure; John Atkinson; Aurore Bouty; Mike O'Brien; Guillaume Levard; John Hutson; Yves Heloury
Journal:  J Pediatr Urol       Date:  2015-09-26       Impact factor: 1.830

7.  DICER1 mutations in familial pleuropulmonary blastoma.

Authors:  D Ashley Hill; Jennifer Ivanovich; John R Priest; Christina A Gurnett; Louis P Dehner; David Desruisseau; Jason A Jarzembowski; Kathryn A Wikenheiser-Brokamp; Brian K Suarez; Alison J Whelan; Gretchen Williams; Dawn Bracamontes; Yoav Messinger; Paul J Goodfellow
Journal:  Science       Date:  2009-06-25       Impact factor: 47.728

8.  DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome.

Authors:  Ingrid Slade; Chiara Bacchelli; Helen Davies; Anne Murray; Fatemeh Abbaszadeh; Sandra Hanks; Rita Barfoot; Amos Burke; Julia Chisholm; Martin Hewitt; Helen Jenkinson; Derek King; Bruce Morland; Barry Pizer; Katrina Prescott; Anand Saggar; Lucy Side; Heidi Traunecker; Sucheta Vaidya; Paul Ward; P Andrew Futreal; Gordan Vujanic; Andrew G Nicholson; Neil Sebire; Clare Turnbull; John R Priest; Kathryn Pritchard-Jones; Richard Houlston; Charles Stiller; Michael R Stratton; Jenny Douglas; Nazneen Rahman
Journal:  J Med Genet       Date:  2011-01-25       Impact factor: 6.318

9.  Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.

Authors:  John G Doench; Nicolo Fusi; Meagan Sullender; Mudra Hegde; Emma W Vaimberg; Jennifer Listgarten; Katherine F Donovan; Ian Smith; Zuzana Tothova; Craig Wilen; Robert Orchard; Herbert W Virgin; David E Root
Journal:  Nat Biotechnol       Date:  2016-01-18       Impact factor: 54.908

10.  Macrocephaly associated with the DICER1 syndrome.

Authors:  Nicholas E Khan; Andrew J Bauer; Leslie Doros; Kris Ann P Schultz; Rosamma M Decastro; Laura A Harney; Ron G Kase; Ann G Carr; Anne K Harris; Gretchen M Williams; Louis P Dehner; Yoav H Messinger; Douglas R Stewart
Journal:  Genet Med       Date:  2016-07-21       Impact factor: 8.822

View more
  4 in total

1.  Two Genetic Mechanisms in Two Siblings with Intellectual Disability, Autism Spectrum Disorder, and Psychosis.

Authors:  Yu-Shu Huang; Ting-Hsuan Fang; Belle Kung; Chia-Hsiang Chen
Journal:  J Pers Med       Date:  2022-06-20

Review 2.  DICER1 Syndrome and Cancer Predisposition: From a Rare Pediatric Tumor to Lifetime Risk.

Authors:  Anna Maria Caroleo; Maria Antonietta De Ioris; Luigi Boccuto; Iside Alessi; Giada Del Baldo; Antonella Cacchione; Emanuele Agolini; Martina Rinelli; Annalisa Serra; Andrea Carai; Angela Mastronuzzi
Journal:  Front Oncol       Date:  2021-01-21       Impact factor: 6.244

3.  A complex DICER1 syndrome phenotype associated with a germline pathogenic variant affecting the RNase IIIa domain of DICER1.

Authors:  Emeli Pontén; Sofia Frisk; Fulya Taylan; Raquel Vaz; Sandra Wessman; Leanne de Kock; Niklas Pal; William D Foulkes; Kristina Lagerstedt-Robinson; Ann Nordgren
Journal:  J Med Genet       Date:  2020-11-18       Impact factor: 6.318

Review 4.  Rare Hereditary Gynecological Cancer Syndromes.

Authors:  Takafumi Watanabe; Shu Soeda; Yuta Endo; Chikako Okabe; Tetsu Sato; Norihito Kamo; Makiko Ueda; Manabu Kojima; Shigenori Furukawa; Hidekazu Nishigori; Toshifumi Takahashi; Keiya Fujimori
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.